Skip to content
Open access

Schisandrin B alleviates hepatic damage and hepatic lipid metabolic dysregulation induced by microcystin-LR.

Sep 2026 · Ecotoxicology and Environmental Safety · Vol 324, pp. 120799 · 0 citations · 25 references
Medicine

TL;DR

Results indicate that SchB attenuates MC-LR-induced hepatic toxicity and suppresses excessive AKT/FOXO1 activation, suggesting SchB as a promising hepatoprotective candidate against MC-LR exposure.

Abstract

Microcystin-LR (MC-LR) is a common biological pollutant found in aquatic environments; it induces severe liver injury, inflammation and lipid metabolic disorders. The potential mechanisms underlying MC-LR pathogenesis is still unclear, and effective therapeutic drugs remain to be explored through in-depth research. This study was designed to systematically evaluate and clarify the protective effects and mechanisms of Schisandrin B (SchB) against MC-LR-induced hepatotoxicity. The animal study indicated that SchB alleviated MC-LR-triggered body weight loss, hepatomegaly, liver dysfunction, inflammatory responses and histopathological damage (all p<0.05). Biochemical analysis and qRT-PCR results demonstrated that SchB ameliorated triglyceride and total cholesterol levels by regulating lipogenic and lipolytic gene expression (all p<0.05). Bioinformatics and molecular docking identified IL-6 as a potential binding target of SchB, with IL-6 was induced by MC-LR. Further, GO and KEGG bioinformatic analysis combined with Western blot demonstrated that SchB attenuated MC-LR-induced excessive AKT-FOXO1 cascade activation (all p<0.05), and SC79, a selective AKT activator, partially reversed the hepatoprotective effects of SchB, as evidenced by altered serum ALT/AST levels, hepatic inflammatory cytokines (TNF-α, IL-6), lipid metabolism-related genes (SREBP1c、SCD1、ACC1、PPARα), and antioxidant indicators (SOD and CAT), a finding further supported by in vivo animal studies (all p<0.05). These results indicate that SchB attenuates MC-LR-induced hepatic toxicity and suppresses excessive AKT/FOXO1 activation, suggesting SchB as a promising hepatoprotective candidate against MC-LR exposure.

Read PDF

Similar papers

Sep 2026

Cyanotoxins induce hepatic inflammation and disrupt lipid metabolism in Sinocyclocheilus grahami

The results showed histopathological hepatic damage across treatments, with a significantly decreased hepatosomatic index (HSI) in the high-PHS-exposure group, and Interestingly, the triglyceride content showed significant increases in the PHS-treated groups.

Jiao-Jiao Li, Jun Li, Xiao-Fu Pan · 0 citations
Open access Oct 2026

Cynaroside Attenuates Ethinylestradiol-Induced Cholestatic Liver Injury by Modulating the FXR/BSEP/CYP7A1/SHP Axis

Cholestatic liver diseases are characterized by disrupted bile acid homeostasis, oxidative stress, and inflammation, ultimately leading to progressive hepatic injury. Although ursodeoxycholic acid (UDCA) remains the standard pharmacological therapy, its therapeutic efficacy is limited in several cholestatic conditions....

Amany M. Hamed, D. Al-Nouri, N. Mahrous et al. · 0 citations
Sep 2026

Mangiferin monosodium salt attenuates metabolic and alcohol-associated liver disease via a novel insight into cuproptosis and improving gut microbiota.

Alcoholic liver disease (ALD) is a major global health burden. Cuproptosis, a form of regulated cell death, plays a critical role in multiple liver diseases, yet its role and mechanisms in ALD remain largely unknown. This study explored the preventive and therapeutic roles of mangiferin monosodium salt (MG-Na) against...

Qing-Qing Zhang, Chong-Zheng Pang, Le-Hua Chen et al. · 0 citations
Open access Sep 2026

Enniatin B attenuates deoxynivalenol-induced toxicity in liver cells and modulates lipid metabolism-related pathways.

Mycotoxin contamination of food and feed is an increasing global health concern, particularly due to Fusarium toxins such as the regulated deoxynivalenol (DON) and the emerging enniatin B (ENNB). However, the combined mechanisms of action of these toxins remain poorly understood. This study aimed to assess their toxic...

D. Habauzit, Sylvie Huet, Emeline Nicolas et al. · 0 citations
Sep 2026

Zearalenone promotes hepatic lipid accumulation via EGFR-HSP90 complex stabilization.

Collectively, ZEA promotes hepatic lipid accumulation via stabilization of the EGFR-HSP90 complex and activation of the EGFR-SREBP1c axis, suggesting EGFR as a potential therapeutic target.

Bing-Xin Huangfu, Teng Wang, Jie Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.